AACR 2024 Poster: Using NGS to Detect KMT2A (MLL) Fusions and KMT2A-PTDs

Abstract
KMT2A (MLL) fusions and KMT2A-PTD (partial tandem duplication) are important biomarkers in myeloid malignancies. This biomarker has garnered much interest, as ongoing clinical trial research has shown that acute leukemias harboring KMT2A rearrangements may be susceptible to small molecule inhibitors that target the KMT2A-menin protein complex¹.

While KMT2A rearrangements are traditionally detected by RT-qPCR (quantitative real-time PCR), a recent study presented at the American Association of Cancer Research (AACR) Annual Meeting 2024 has demonstrated the use of next-generation sequencing (NGS) with the Oncomine Myeloid Assay GX v2 on the Ion Torrent Genexus System to detect KMT2A fusions in myeloid malignancy samples and KMT2A-PTDs in both healthy donors and myeloid malignancy samples.

Detection of KMT2A-PTDs in healthy donor and myeloid malignant samples using next generation sequencing
Jiajie Huang, et al.

Please fill out the form below to download this poster.

First name

Last name

Company / institution

Country / region

Zip / postal code

City

Phone number

Job Role (optional)

I would like to receive a quote or demonstration of NGS solutions for myeloid genomic profiling.

I would like Thermo Fisher Scientific (including its affiliates) to add me to a list to receive information about events, products, services and promotions which Thermo Fisher believes may be of interest to me via the following channels:

Phone

I can withdraw my consent and unsubscribe at any time by e-mailing reply@thermofisher.com

I acknowledge Thermo Fisher Scientific (including its affiliates) will process my personal information according to its Privacy Policy, which includes information about my rights.

¹Swaminathan, et al. Cancer J. 2022 Jan-Feb;28(1):62-66.

For Research Use Only. Not for Use in Diagnostic Procedures.